The Claim
In adults with atherosclerotic cardiovascular disease, plasma concentrations of obicetrapib are strongly inversely correlated with changes in p-tau217 (r = −0.64), indicating a dose-dependent biological effect of CETP inhibition on Alzheimer’s disease biomarkers.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with atherosclerotic cardiovascular disease, higher levels of obicetrapib in the blood are associated with lower levels of p-tau217, a biomarker linked to Alzheimer’s disease.
See the scientific wording
In adults with atherosclerotic cardiovascular disease, plasma concentrations of obicetrapib are strongly inversely correlated with changes in p-tau217 (r = −0.64), suggesting a dose-dependent biological effect of CETP inhibition on Alzheimer’s disease biomarkers.
A drug that blocks a protein called CETP increases healthy fat particles in the blood that carry antioxidants and cholesterol-clearing molecules into the brain. These particles remove excess cholesterol and toxic fats from brain cells, reduce damage from oxidative stress, and stop the buildup of abnormal tau protein. The more of the drug in the blood, the more this process happens, leading to less abnormal tau in the brain.
What the research says
1 studyIn people with heart disease, taking more of the drug obicetrapib was linked to bigger drops in a brain protein linked to Alzheimer’s, meaning the drug may be working in the brain—and the more you have in your blood, the stronger the effect.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.